Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2024-07-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the safety of rituximab plus cyclophosphamide,
doxorubicin, vincristine,prednisone (R-CHOP) in HIV-infected and HIV-uninfected diffuse large
B-cell lymphoma (DLBCL) patients in Malawi.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborators:
Fogarty International Center of the National Institute of Health John E. Fogarty International Center (FIC) National Cancer Institute (NCI) National Institutes of Health (NIH)